

Supplemental File 1. CONSORT checklist for pragmatic randomized controlled trials

SECTION and topic	Item #	Descriptor¹	Reported on page #
TITLE & ABSTRACT	1	How participants were allocated to interventions (e.g., "random allocation", "randomized", or "randomly assigned").	2
INTRODUCTION			
Background	2	Scientific background and explanation of rationale. EXT: Describe the health or health service problem that the intervention is intended to address and other interventions that may commonly be aimed at this problem.	6
METHODS			
Participants	3	Eligibility criteria for participants and the settings and locations where the data were collected. EXT: Eligibility criteria should be explicitly framed to show the degree to which they include typical participants and/or, where applicable, typical providers (eg, nurses), institutions (eg, hospitals), communities (or localities eg, towns) and settings of care (eg, different healthcare financing systems).	8

SECTION and topic	Item #	Descriptor ¹	Reported on page #
Interventions	4	<p>Precise details of the interventions intended for each group and how and when they were actually administered.</p> <p>EXT: Describe extra resources added to (or resources removed from) usual settings in order to implement intervention. Indicate if efforts were made to standardise the intervention or if the intervention and its delivery were allowed to vary between participants, practitioners, or study sites. Describe the comparator in similar detail to the intervention</p>	9, 12
Objectives	5	Specific objectives and hypotheses.	8
Outcomes	6	<p>Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).</p> <p>EXT: Explain why the chosen outcomes and, when relevant, the length of follow-up are considered important to those who will use the results of the trial</p>	5, 22
Sample size	7	<p>How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules.</p> <p>EXT: If calculated using the smallest difference considered important by the target decision maker audience (the minimally important difference) then report where this difference was obtained</p>	21

SECTION and topic	Item #	Descriptor ¹	Reported on page #
Randomization:			
Sequence generation	8	Method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, stratification).	12
Allocation concealment	9	Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	12
Implementation	10	Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.	12
Blinding (Masking)	11	Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. If done, how the success of blinding was evaluated. EXT: If blinding was not done, or was not possible, explain why	18
Statistical methods	12	Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses, such as subgroup analyses and adjusted analyses.	20
RESULTS			

SECTION and topic	Item #	Descriptor ¹	Reported on page #
Participant flow	13	<p>Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons.</p> <p>EXT: The number of participants or units approached to take part in the trial, the number which were eligible, and reasons for nonparticipation should be reported</p>	19
Recruitment	14	Dates defining the periods of recruitment and follow-up.	n/a
Baseline data	15	Baseline demographic and clinical characteristics of each group.	n/a
Numbers analyzed	16	Number of participants (denominator) in each group included in each analysis and whether the analysis was by intention-to-treat". State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	17
Outcomes and Estimation	17	For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision (e.g., 95% confidence interval).	n/a

SECTION and topic	Item #	Descriptor ¹	Reported on page #
Ancillary analyses	18	Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	n/a
Adverse events	19	All important adverse events or side effects in each intervention group.	n/a
DISCUSSION			
Interpretation	20	Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	n/a
Generalizability	21	Generalizability (external validity) of the trial findings. EXT: Describe key aspects of the setting which determined the trial results. Discuss possible differences in other settings where clinical traditions, health service organisation, staffing, or resources may vary from those of the trial.	n/a
Overall evidence	22	General interpretation of the results in the context of current evidence.	n/a

¹ EXT denotes a pragmatic trial extension of the CONSORT statement.

<https://www.bmj.com/content/bmj/337/bmj.a2390.full.pdf>